Acme United (ACU) Q4 2025 earnings review
Steady Growth Masks Domestic Tariff Pressures
Acme United delivered a solid finish to 2025, with Q4 sales up 3% to $47.5M and EPS jumping 12% to $0.46. However, the headline growth was driven entirely by international markets (Europe +31%, Canada +14%) and strategic acquisitions, while the core U.S. segment stagnated (0% growth) due to severe tariff-related disruptions in school and office products. Management continues to leverage its strong balance sheet, acquiring My Medic for $18.7M in January 2026 to add $19M in revenue, and generating $13.6M in free cash flow to further reduce debt.
🐂 Bull Case
The $18.7M My Medic acquisition immediately adds ~$19M in high-margin direct-to-consumer revenue, while the German cutting tools acquisition contributed $0.5M in Q4 alone.
Europe grew 31% in Q4 and Canada grew 14%, proving that non-U.S. diversification is successfully offsetting domestic weakness.
🐻 Bear Case
The U.S. segment, Acme's largest, saw flat sales in Q4 and a 1% decline for the full year, plagued by retailer cancellations of school and office products due to tariff chaos.
Q4 Gross margin compressed by 50 bps to 38.2% from 38.7% a year ago, snapping a streak of full-year margin expansion, as tariff costs outweighed productivity gains.
⚖️ Verdict: ⚪
Neutral to slightly Bullish. The core U.S. business is struggling with macro headwinds, but Acme's robust cash generation, falling debt, and aggressive M&A strategy provide a clear path to double-digit revenue growth in 2026.
Key Themes
First Aid Segment Drives Growth via Strategic M&A
First Aid continues to be the primary growth engine, offsetting weakness in other categories. The trend is accelerating. The January 2026 acquisition of My Medic expands this dominance into the tactical and trauma direct-to-consumer space. Furthermore, the company is heavily investing in capacity, highlighted by a new $6 million manufacturing and distribution facility in Tennessee for the Spill Magic product line to support ongoing demand.
International Segments Accelerating Sharply
European and Canadian segments are accelerating and carrying the weight of the top line. In Q4, European net sales spiked 31% in USD (22% in local currency), partially aided by a $0.5M contribution from a new German cutting tools acquisition. Canada matched this strength with a 14% increase in both USD and local currency, driven heavily by first-aid products. This geographic diversification is proving critical while the U.S. market stalls.
Cash Flow Generation Remains Stable
Acme generated a stable and robust $13.6M in free cash flow (before the $6M Tennessee facility purchase) during 2025. This cash engine allowed the company to pay $2.3M in dividends, fund the German cutting tools acquisition for $1.6M, and significantly reduce net bank debt. This deleveraging provides the dry powder needed for the subsequent My Medic acquisition without stressing the balance sheet.
U.S. Core Segment Growth Decelerating
Acme's U.S. business, its largest segment, is decelerating. After growing 12% in 24Q4, U.S. sales dropped to -5% in 25Q2, recovered slightly to +1% in 25Q3, and flattened to 0% in 25Q4. Management explicitly blames tariff uncertainty, which caused retailers to postpone or cancel promotions for school and office products. While management notes improvement in retail activity, the domestic top line remains a structural concern until ordering normalizes.
Q4 Gross Margin Reversing
Despite full-year gross margin expanding to 39.4%, Q4 saw a reversing trend, with gross margin compressing 50 basis points to 38.2% from 38.7% a year ago. This contradicts the positive narrative of continuous productivity improvements and indicates that sudden tariff impositions, supply chain shifts, and lower-margin product mix are beginning to pressure unit economics.
Tariff Chaos Disrupting Retail Channels
Macro environment remains unstable. Tariffs were suddenly imposed in April 2025 and changed abruptly multiple times throughout the year. This created a chaotic environment for Acme's retail customers, directly leading to order cancellations. While Acme has structurally diversified its supply chain to countries like Egypt and Thailand, the immediate macroeconomic shocks still severely disrupted its Westcott and office product lines.
Other KPIs
Accelerating. FCF remains a highlight, ending at $13.6M before a $6M facility investment, a significant jump from $5.0M in FY24. This enabled rapid debt paydown and funded the $2.3M dividend.
Stable. Inventories rose modestly to $59.9M from $56.3M a year ago. This intentional build helps buffer against supply chain shocks and tariff uncertainty, ensuring Acme can meet customer demand when competitors stock out.
The January 2026 acquisition of My Medic for $18.7M represents a massive top-line catalyst. With ~$19M in 2025 revenues, this single acquisition could add nearly 10% to Acme's total top line in 2026, pivoting the company deeper into high-margin, direct-to-consumer tactical first aid.
Key Questions
My Medic Margin Profile
My Medic brings $19M in direct-to-consumer revenue. Does this carry a higher gross margin profile than the legacy first aid business, and how much SG&A overlap can be eliminated?
Tariff Pricing Power
With Q4 gross margins compressing by 50 bps, to what extent are you able to pass new tariff costs onto retail partners, and will pricing actions risk further order cancellations in 2026?
Retail Rebound Durability
You noted an 'improvement in retail activity' recently. Is this a return to normal ordering patterns, or just a temporary restocking of depleted inventories after prolonged back-to-school cancellations?